Stock Track | Burning Rock Biotech Plunges 5% as CFO Resigns

Stock Track09-27

Shares of Burning Rock Biotech Limited (NASDAQ: BNR) plummeted by 5.31% on Thursday, September 27, 2024, following the resignation of its Chief Financial Officer and board director, Leo Li, for personal reasons.

According to the company's announcement, Mr. Li's resignation was effective September 27, 2024, and was not due to any disagreement with the Board, the company, or its affiliates regarding operations, policies, or practices. Burning Rock stated that Mr. Li confirmed he has no claims against the company.

In light of Mr. Li's departure, Xiaozhi Hu, the senior director in finance, will oversee the company's financial operations, financial reporting, and related matters. Ms. Hu will report directly to Yusheng Han, the chairman of the board and chief executive officer. Mr. Han expressed gratitude for Mr. Li's contributions during his tenure, particularly during the company's initial public offering and subsequent business development projects.

Burning Rock Biotech Limited, based in Guangzhou, China, is focused on the application of next-generation sequencing (NGS) technology in precision oncology. The company's business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed into the clinical validation stage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment